U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

"By the time the symptoms of dementia and other neurological diseases appear it is already too late," said Prof Sumeet ...

The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Alzheimer’s disease is the leading cause of dementia in the UK. It’s a complex, challenging, and devastating condition that causes a gradual decline in a person’s cognition, including memory and ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...

Nikon Small World photomicrography contest is an annual reminder that science can be beautiful as well as informative.

A study suggests that menopausal hormone therapy (MHT) might have moderate effects on brain health, but this depends on past ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...